The study, published in the Annals of Internal Medicine, examined the safety and efficacy of Flu-v, a broad-spectrum flu vaccine that could become the highly anticipated universal flu vaccine, offering long-lasting protection and doing away with the need for annual flu shots.
Flu-v has been through phase 1 clinical trials that demonstrated it is safe. The current study is a phase 2 study and involved 175 healthy adults. The study participants were divided into two groups: one receiving Flu-v and the other receiving a placebo.
Researchers found that Flu-v elicited greater immune responses than a placebo, suggesting the vaccine increases the production of antibodies in the body.
The vaccine will now be tested for its effectiveness against flu infection in phase 3 clinical trials.
More articles on infection control:
Use of 2 central line catheters at once can up CLABSI risk, study shows
Here’s how a Hong Kong hospital tested 1,275 for coronavirus, and no employees got sick
14-day quarantine for coronavirus is appropriate, study suggests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
